Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3008207rdf:typepubmed:Citationlld:pubmed
pubmed-article:3008207lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0025219lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0009035lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0026457lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0040778lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C2709058lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:3008207lifeskim:mentionsumls-concept:C0086130lld:lifeskim
pubmed-article:3008207pubmed:issue2lld:pubmed
pubmed-article:3008207pubmed:dateCreated1986-5-15lld:pubmed
pubmed-article:3008207pubmed:abstractTextMelatonin was measured in plasma collected between 8:00 and 8:30 a.m. from 27 depressed patients studied before and after 21- to 24-day treatment with three monoamine oxidase (MAO) inhibitors. Baseline plasma melatonin concentrations determined by radioimmunoassay were 4.0 +/- SD 4.7 pg/ml. Tranylcypromine, a nonselective MAO inhibitor given in doses of 20-40 mg/day for 3 weeks, significantly elevated plasma melatonin to 10.6 +/- SD 2.0 pg/ml. Clorgyline, given in doses of 15-30 mg/day for 3 weeks, produced a significant, approximately three-fold increase in plasma melatonin (13.6 +/- SD 13.5 pg/ml). This clorgyline dose was selective for MAO type A inhibition, as MAO-B activity measured in platelets from the same blood samples was unaffected by clorgyline. In contrast, the selective MAO-B inhibitor deprenyl (10-30 mg/day for 3 weeks) led to a 96 +/- 4% inhibition of platelet MAO-B activity but no significant change in plasma melatonin (5.1 +/- SD 4.2 pg/ml). As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.lld:pubmed
pubmed-article:3008207pubmed:languageenglld:pubmed
pubmed-article:3008207pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:citationSubsetIMlld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3008207pubmed:statusMEDLINElld:pubmed
pubmed-article:3008207pubmed:monthFeblld:pubmed
pubmed-article:3008207pubmed:issn0165-1781lld:pubmed
pubmed-article:3008207pubmed:authorpubmed-author:MurphyD LDLlld:pubmed
pubmed-article:3008207pubmed:authorpubmed-author:CohenR MRMlld:pubmed
pubmed-article:3008207pubmed:authorpubmed-author:TamarkinLLlld:pubmed
pubmed-article:3008207pubmed:authorpubmed-author:SunderlandTTlld:pubmed
pubmed-article:3008207pubmed:authorpubmed-author:GarrickN ANAlld:pubmed
pubmed-article:3008207pubmed:issnTypePrintlld:pubmed
pubmed-article:3008207pubmed:volume17lld:pubmed
pubmed-article:3008207pubmed:ownerNLMlld:pubmed
pubmed-article:3008207pubmed:authorsCompleteYlld:pubmed
pubmed-article:3008207pubmed:pagination119-27lld:pubmed
pubmed-article:3008207pubmed:dateRevised2008-4-17lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:meshHeadingpubmed-meshheading:3008207-...lld:pubmed
pubmed-article:3008207pubmed:year1986lld:pubmed
pubmed-article:3008207pubmed:articleTitleHuman plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.lld:pubmed
pubmed-article:3008207pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3008207pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3008207lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3008207lld:pubmed